70%Confidence
0Views
SEC EDGARSource
2026-03-24Date
Summary
Harrow filed an 8-K, pointing to a material development for this pharmaceutical company. Given Harrow's focus on ophthalmology, this might involve drug approvals, acquisitions, or financial updates critical to its growth trajectory.
Actionable: Analyze Harrow's 8-K filing to determine the event's impact on its product portfolio and financial outlook.
AI Confidence: 70%
Data Points
companyHARROW, INC. (HROW) (CIK 0001360214)
form8-K
date2026-03-24
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now